Cargando…
ABNCoV2-cVLP-based-COVID-2019-vaccine-AdaptVac: Membranous glomerulopathy and diffuse lupus nephritis: 2 case reports
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602499/ http://dx.doi.org/10.1007/s40278-021-05484-4 |
Ejemplares similares
-
A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
por: Goksøyr, Louise, et al.
Publicado: (2022) -
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2
por: Smit, Merel J, et al.
Publicado: (2023) -
Lupus-Mediated Kidney Damage: Lupus Nephritis or Collapsing Glomerulopathy?
por: De La Cruz, Angel, et al.
Publicado: (2021) -
Lupus Nephritis With Collapsing Glomerulopathy: A Rare Association
por: Dubey, Shubham, et al.
Publicado: (2023) -
IMMUNOLOGIC STUDIES OF ENTERIC CORONAVIRUS-LIKE PARTICLES(CVLP)
por: Lund, Mary E, et al.
Publicado: (1984)